Vyome’s VT-1953 Phase 2 data signals breakthrough in malignant fungating wound care
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.
Pharma & Biotech
Pharma & Biotech
Why Vyome’s VT-1953 data could reshape supportive oncology care in advanced cancer wounds
Vyome’s VT-1953 heads to AACR 2026 with Phase 2 data in malignant fungating wounds. Read what this could change for supportive oncology.